De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway

Histopathology

Volumn 57, Issue 6, 2010, Pages 836-850

  Fritsche Guenther, Raphaela ^a   Noske, Aurelia ^a   Ungethüm, Ute ^a   Kuban, Ralf Jürgen ^a   Schlag, Peter M ^a   Tunn, Per Ulf ^a   Karle, Janine ^a   Krenn, Veit ^b   Dietel, Manfred ^a   Sers, Christine ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Centre for Histology Cytology and Molecular Diagnostics   (Germany)

Author keywords

EFNA1; EphA2; MAPK; Osteosarcoma

Indexed keywords

EPHRIN A1; EPHRIN A3; EPHRIN B1; EPHRIN B3; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A3; MITOGEN ACTIVATED PROTEIN KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOREGULATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWNSTREAM PROCESSING; DRUG TARGETING; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INTERNALIZATION; LIGAND BINDING; MALE; MITOGENESIS; MODULATION; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; BLOTTING, WESTERN; BONE NEOPLASMS; CHILD; EPHRIN-A1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PHOSPHORYLATION; RECEPTOR, EPHA2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 78650255274     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03713.x     Document Type: Article

References (34)

1. Campanacci M. Bone tumors. 2nd edn. Lippincott-Verlag, Bologna, Italy. 1999; 1418-1468.
2. Gelberg KH, Fitzgerald EF, Hwang S, Dubrow R. Growth and development and other risk factors for osteosarcoma in children and young adults. Int. J. Epidemiol. 1997; 26; 272-278.
3. Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J. Surg. Oncol. 1972; 4; 482-510.
4. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 1999; 341; 342-352.
5. Guenther R, Krenn V, Morawietz L et al. Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol. Res. Pract. 2005; 201; 649-663.
6. Varelias A, Koblar SA, Cowled PA, Carter CD, Clayer M. Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis. Cancer 2002; 95; 862-869.
7. Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res. 2009; 69; 2072-2081.
8. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004; 15; 419-433.
9. Dong Y, Wang J, Sheng Z et al. Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod. Pathol. 2009; 22; 151-160.
10. Herath NI, Doecke J, Spanevello MD, Leggett BA, Boyd AW. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br. J. Cancer 2009; 100; 1095-1102.
11. Taddei ML, Parri M, Angelucci A et al. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am. J. Pathol. 2009; 174; 1492-1503.
12. Oike Y, Ito Y, Hamada K et al. Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood 2002; 100; 1326-1333.
13. Remmele W, Stegner H. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8; 138-140.
14. Macrae M, Neve RM, Rodriguez-Viciana P et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005; 8; 111-118.
15. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002; 21; 7690-7699.
16. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Diff. 1999; 10; 629-638.
17. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005; 24; 7859-7868.
18. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol. Cancer Res. 2007; 5; 283-293.
19. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J. Cancer Res. Clin. Oncol. 2008; 134; 281-297.
20. Kaya M, Wada T, Akatsuka T et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin. Cancer Res. 2000; 6; 572-577.
21. Onda M, Matsuda S, Higaki S et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996; 77; 71-78.
22. Coltella N, Manara MC, Cerisano V et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 2003; 17; 1162-1164.
23. Kido A, Tsutsumi M, Iki K et al. Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in rats. Cancer Lett. 1999; 137; 209-216.
24. Saito T, Masuda N, Miyazaki T et al. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol. Rep. 2004; 11; 605-611.
25. Brantley DM, Cheng N, Thompson EJ et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21; 7011-7026.
26. Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J. Cell Sci. 2004; 117; 2037-2049.
27. Batlle E, Bacani J, Begthel H et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005; 435; 1126-1130.
28. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res. 2007; 67; 3994-3997.
29. Bartley TD, Hunt RW, Welcher AA et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 1994; 368; 558-560.
30. Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 2008; 27; 7260-7273.
31. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 2005; 208; 126-140.
32. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2000; 2; 62-69.
33. Parri M, Buricchi F, Taddei ML et al. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J. Biol. Chem. 2005; 280; 34008-34018.
34. Noberini R, Koolpe M, Peddibhotla S et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J. Biol. Chem. 2008; 283; 29461-29472.